JP2013508279A5 - - Google Patents

Download PDF

Info

Publication number
JP2013508279A5
JP2013508279A5 JP2012534259A JP2012534259A JP2013508279A5 JP 2013508279 A5 JP2013508279 A5 JP 2013508279A5 JP 2012534259 A JP2012534259 A JP 2012534259A JP 2012534259 A JP2012534259 A JP 2012534259A JP 2013508279 A5 JP2013508279 A5 JP 2013508279A5
Authority
JP
Japan
Prior art keywords
compound
group
salt
alkyl
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2012534259A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013508279A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2010/052126 external-priority patent/WO2011046851A1/en
Publication of JP2013508279A publication Critical patent/JP2013508279A/ja
Publication of JP2013508279A5 publication Critical patent/JP2013508279A5/ja
Withdrawn legal-status Critical Current

Links

JP2012534259A 2009-10-15 2010-10-11 スピロピペリジン化合物および糖尿病治療のためのその医薬用途 Withdrawn JP2013508279A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US25183909P 2009-10-15 2009-10-15
US61/251,839 2009-10-15
US30333410P 2010-02-11 2010-02-11
US61/303,334 2010-02-11
PCT/US2010/052126 WO2011046851A1 (en) 2009-10-15 2010-10-11 Spiropiperidine compounds and pharmaceutical use thereof for treating diabetes

Publications (2)

Publication Number Publication Date
JP2013508279A JP2013508279A (ja) 2013-03-07
JP2013508279A5 true JP2013508279A5 (enExample) 2013-11-07

Family

ID=43719548

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012534259A Withdrawn JP2013508279A (ja) 2009-10-15 2010-10-11 スピロピペリジン化合物および糖尿病治療のためのその医薬用途

Country Status (25)

Country Link
US (1) US8383642B2 (enExample)
EP (1) EP2488500A1 (enExample)
JP (1) JP2013508279A (enExample)
KR (1) KR20120051777A (enExample)
CN (1) CN102574807A (enExample)
AR (1) AR078522A1 (enExample)
AU (1) AU2010307094A1 (enExample)
BR (1) BR112012008889A2 (enExample)
CA (1) CA2777775A1 (enExample)
CL (1) CL2012000921A1 (enExample)
CO (1) CO6531458A2 (enExample)
CR (1) CR20120177A (enExample)
DO (1) DOP2012000105A (enExample)
EA (1) EA201270560A1 (enExample)
EC (1) ECSP12011799A (enExample)
IL (1) IL218344A0 (enExample)
MA (1) MA33662B1 (enExample)
MX (1) MX2012004420A (enExample)
NZ (1) NZ598972A (enExample)
PE (1) PE20121437A1 (enExample)
PH (1) PH12012500705A1 (enExample)
TN (1) TN2012000152A1 (enExample)
TW (1) TW201124415A (enExample)
WO (1) WO2011046851A1 (enExample)
ZA (1) ZA201202560B (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI1013559A2 (pt) 2009-03-23 2016-04-12 Glenmark Pharmaceuticals Sa compostos, composição farmacêutica, método de tratamento de doença ou condição associada à função trpa1 e respectivos usos
EP2411395B1 (en) 2009-03-23 2013-05-29 Glenmark Pharmaceuticals S.A. Furopyrimidinedione derivatives as trpa1 modulators
AR078948A1 (es) 2009-11-30 2011-12-14 Lilly Co Eli Compuestos de espiropiperidina, composicion farmaceutica que lo comprenden y su uso para preparar un medicamento util para tratar la diabetes
US8476287B2 (en) 2009-12-25 2013-07-02 Mochida Pharmaceutical Co., Ltd. 3-hydroxy-5-arylisothiazole derivative
JP5809157B2 (ja) 2010-10-08 2015-11-10 持田製薬株式会社 環状アミド誘導体
ES2891092T3 (es) 2011-03-11 2022-01-26 Intercontinental Great Brands Llc Método de conformación de producto de confitería de múltiples capas
CA2834417A1 (en) 2011-04-27 2012-11-01 Mochida Pharmaceutical Co., Ltd. Novel 3-hydroxyisothiazole 1-oxide derivative
CA2834465A1 (en) 2011-04-28 2012-11-01 Mochida Pharmaceutical Co., Ltd. Cyclic amide derivative
TWI537262B (zh) 2011-08-17 2016-06-11 美國禮來大藥廠 供治療糖尿病使用之新穎1,2,3,4-四氫喹啉衍生物
WO2013139341A1 (en) * 2012-03-20 2013-09-26 Syddansk Universitet Gpr120 receptor modulators
WO2013185766A1 (en) * 2012-06-15 2013-12-19 Syddansk Universitet Gpr120 receptor modulators
PT2920165T (pt) 2012-11-16 2016-12-20 Bristol Myers Squibb Co Moduladores de diidropirazol gpr40
KR101569522B1 (ko) * 2013-04-18 2015-11-17 현대약품 주식회사 신규한 3-(4-(벤질옥시)페닐)헥스-4-이노익 산 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 대사성 질환의 예방 또는 치료용 약학적 조성물
AU2014372114A1 (en) * 2013-11-14 2016-06-09 Cadila Healthcare Limited Novel heterocyclic compounds
US20150351889A1 (en) 2014-06-05 2015-12-10 Vivex Biomedical Inc. Dynamic Biometric Mesh
BR112017007720B1 (pt) * 2014-10-17 2023-01-17 Hyundai Pharm Co., Ltd. Composição contendo derivado de ácido 3-(4-(benzilóxi)fenil)hex-4-inoico e outro princípio ativo para prevenir ou tratar doenças metabólicas
CN109666027A (zh) * 2017-10-17 2019-04-23 中国科学院上海药物研究所 一类酰胺结构的gpr40激动剂化合物及其用途
MX2020007283A (es) 2018-01-08 2020-09-10 Celon Pharma Sa Derivados de acido 3-fenil-4-hexinoico como agonistas del receptor acoplado a la proteina g-40.
WO2019160882A1 (en) 2018-02-13 2019-08-22 Gilead Sciences, Inc. Pd-1/pd-l1 inhibitors
WO2019204609A1 (en) 2018-04-19 2019-10-24 Gilead Sciences, Inc. Pd-1/pd-l1 inhibitors
BR112020026746A2 (pt) 2018-07-13 2021-03-30 Gilead Sciences, Inc. Composto, composição farmacêutica, métodos para inibir pd-1, pd-l1 e/ou a interação de pd-1/pd-l1 e para tratar câncer, e, kit para tratar ou prevenir câncer ou uma doença ou condição.
CN112955435B (zh) 2018-10-24 2024-09-06 吉利德科学公司 Pd-1/pd-l1抑制剂
JP2022552655A (ja) 2019-10-07 2022-12-19 キャリーオペ,インク. Gpr119アゴニスト
PH12022552277A1 (en) 2020-02-28 2024-03-04 Kallyope Inc Gpr40 agonists
JP2023526625A (ja) 2020-05-19 2023-06-22 キャリーオペ,インク. Ampkアクチベーター
CN116390925A (zh) 2020-06-26 2023-07-04 卡尔优普公司 Ampk活化剂

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6828440B2 (en) 2001-04-18 2004-12-07 Euro-Celtique, S.A. Spiroindene and spiroindane compounds
CN101108825A (zh) * 2003-04-04 2008-01-23 麦克公司 作为黑皮质素-4受体激动剂的酰化螺哌啶衍生物
EP1682136A4 (en) 2003-11-04 2009-06-03 Elixir Pharmaceuticals Inc THERAPEUTIC COMPOUNDS AND CORRESPONDING USES THEREOF
WO2005051890A1 (en) 2003-11-19 2005-06-09 Smithkline Beecham Corporation Aminophenylcyclopropyl carboxylic acids and derivatives as agonists to gpr40
EA011010B1 (ru) 2004-02-27 2008-12-30 Эмджен, Инк. Соединения, модулирующие рецептор gpr40, фармацевтическая композиция, способ лечения заболеваний, чувствительных к модулированию рецептора gpr40 (варианты), способ модулирования функции gpr40 (варианты) и способ модулирования циркулирующей концентрации инсулина
EP1731505B1 (en) * 2004-03-30 2015-01-14 Takeda Pharmaceutical Company Limited Alkoxyphenylpropanoic acid derivatives
WO2007033002A1 (en) 2005-09-14 2007-03-22 Amgen Inc. Conformationally constrained 3- (4-hydroxy-phenyl) - substituted-propanoic acids useful for treating metabolic disorders
WO2008030618A1 (en) 2006-09-07 2008-03-13 Amgen Inc. Benzo-fused compounds for use in treating metabolic disorders
AR071055A1 (es) 2007-10-26 2010-05-26 Japan Tobacco Inc Compuestos espiro, composiciones farmaceuticas y medicamentos que los comprenden, agente promotor de la secrecion de insulina y usos para la preparacion de medicamentos y composiciones farmaceuticas
US8158792B2 (en) 2007-11-21 2012-04-17 Janssen Pharmaceutica N.V. Spiropiperidines for use as tryptase inhibitors
AR078948A1 (es) 2009-11-30 2011-12-14 Lilly Co Eli Compuestos de espiropiperidina, composicion farmaceutica que lo comprenden y su uso para preparar un medicamento util para tratar la diabetes

Similar Documents

Publication Publication Date Title
JP2013508279A5 (enExample)
JP2013512277A5 (enExample)
JP2013518107A5 (enExample)
JP2012525393A5 (enExample)
JP2013542247A5 (enExample)
JP2009535307A5 (enExample)
JP2010077141A5 (enExample)
JP2014511891A5 (enExample)
JP2013537203A5 (enExample)
JP2012505836A5 (enExample)
JP2013510120A5 (enExample)
JP2009535352A5 (enExample)
JP2013509429A5 (enExample)
JP2011504903A5 (enExample)
JP2009523760A5 (enExample)
JP2011528713A5 (enExample)
JP2013507439A5 (enExample)
JP2009504763A5 (enExample)
JP2014505107A5 (enExample)
JP2014518266A5 (enExample)
JP2014508804A5 (enExample)
JP2020507589A5 (enExample)
JP2007302689A5 (enExample)
JP2011246469A5 (enExample)
JP2010522710A5 (enExample)